

Chukwuka Eze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8990281/publications.pdf>

Version: 2024-02-01

105
papers

834
citations

516710

16
h-index

580821

25
g-index

108
all docs

108
docs citations

108
times ranked

1069
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent advances of PET imaging in clinical radiation oncology. <i>Radiation Oncology</i> , 2020, 15, 88.	2.7	75
2	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	5.0	61
3	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. <i>Radiation Oncology</i> , 2018, 13, 37.	2.7	54
4	Impact of ⁶⁸ Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 963-970.	5.0	44
5	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. <i>Radiation Oncology</i> , 2017, 12, 176.	2.7	34
6	Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 79-90.	2.0	30
7	Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. <i>Radiation Oncology</i> , 2020, 15, 167.	2.7	29
8	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2020, 15, 5.	2.7	28
9	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	6.4	25
10	Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. <i>Investigational New Drugs</i> , 2021, 39, 1189-1196.	2.6	25
11	Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate. <i>Radiation Oncology</i> , 2022, 17, 53.	2.7	24
12	Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging. <i>Clinical Lung Cancer</i> , 2017, 18, e243-e249.	2.6	23
13	Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature. <i>Journal of Immunotherapy</i> , 2018, 41, 96-99.	2.4	23
14	Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 107-115.	2.0	22
15	Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 49-55.	2.7	20
16	Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. <i>Cancers</i> , 2021, 13, 1613.	3.7	18
17	Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. <i>Anticancer Research</i> , 2019, 39, 5077-5081.	1.1	17
18	State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey. <i>European Journal of Cancer</i> , 2019, 108, 50-54.	2.8	17

#	ARTICLE	IF	CITATIONS
19	Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. <i>Radiation Oncology</i> , 2020, 15, 148.	2.7	17
20	MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience. <i>Radiation Oncology</i> , 2022, 17, 8.	2.7	15
21	Stereotactic Body Radiation Therapy (SBRT) Combined with Immune Check-Point Inhibition (ICI) in Advanced Lung Cancer: Which Metastatic Site Should Be Irradiated to Induce Immunogenic Cell Death?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 225-226.	0.8	14
22	Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 150-155.	2.0	13
23	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1417-1428.	6.4	13
24	Prophylactic Cranial Irradiation in Resected Early-Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 612-614.	0.8	12
25	Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 593-604.	2.8	12
26	How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2103-2109.	6.4	11
27	Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis. <i>Cancers</i> , 2020, 12, 3035.	3.7	10
28	Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis. <i>Radiation Oncology</i> , 2019, 14, 163.	2.7	9
29	MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients. <i>Radiation Oncology</i> , 2022, 17, 43.	2.7	9
30	Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. <i>BMC Cancer</i> , 2016, 16, 216.	2.6	7
31	Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. <i>Frontiers in Oncology</i> , 2017, 7, 88.	2.8	7
32	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. <i>Cancers</i> , 2020, 12, 3395.	3.7	7
33	PSMA-positive nodal recurrence in prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 637-646.	2.0	7
34	Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 11.	7.1	6
35	Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) – a German radiation oncology survey. <i>Translational Lung Cancer Research</i> , 2020, 9, 288-293.	2.8	6
36	Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer. <i>In Vivo</i> , 2021, 35, 929-935.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1341.	7.1	6
38	Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest. <i>Annals of Oncology</i> , 2017, 28, 2319-2320.	1.2	5
39	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	2.8	5
40	Maximum standardized uptake value of primary tumor (SUV _{max} _PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 541-548.	2.8	5
41	Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. <i>Investigational New Drugs</i> , 2021, , 1.	2.6	5
42	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. <i>Frontiers in Oncology</i> , 2021, 11, 723536.	2.8	5
43	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy and immune checkpoint inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1407-1416.	6.4	5
44	Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer: A Prospective Longitudinal Assessment. <i>Diagnostics</i> , 2021, 11, 1968.	2.6	5
45	External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. <i>Lung</i> , 2020, 198, 201-206.	3.3	4
46	Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. <i>Anticancer Research</i> , 2020, 40, 2319-2322.	1.1	4
47	Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report. <i>Radiation Oncology Journal</i> , 2017, 35, 180-184.	1.5	4
48	Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey. <i>Anticancer Research</i> , 2018, 38, 5261-5265.	1.1	3
49	Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. <i>Frontiers in Oncology</i> , 2021, 11, 708595.	2.8	3
50	Novel modified patient immobilisation device with an integrated coil support system for MR-guided online adaptive radiotherapy in the management of brain and head-and-neck tumours. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 20, 35-40.	1.9	3
51	PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, , .	4.6	3
52	Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. <i>Journal of Cancer</i> , 2016, 7, 2012-2017.	2.5	2
53	Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role. <i>Journal of Thoracic Oncology</i> , 2017, 12, e137-e138.	1.1	2
54	Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study. <i>Acta Oncologica</i> , 2021, 60, 1074-1078.	1.8	2

#	ARTICLE	IF	CITATIONS
55	Novel Multimodal Management of Post-Partum Synchronous Metastatic Pulmonary EBV-Associated Lymphoepithelioma-Like Carcinoma (LELC) – A Case Report. <i>Diagnostics</i> , 2021, 11, 2072.	2.6	2
56	Prophylactic cranial irradiation in small-cell lung cancer. <i>Lancet Oncology</i> , The, 2017, 18, e366.	10.7	1
57	Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies. <i>Annals of Oncology</i> , 2017, 28, ii42.	1.2	1
58	18F-FDG-PET/CT for the Visualization of Inflammatory Component of Radiation-Induced Lung Injury After Stereotactic Radiotherapy. <i>Clinical Nuclear Medicine</i> , 2018, 43, e87-e88.	1.3	1
59	In Regard to You et Al and TeixidÀ³ et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 465-466.	0.8	1
60	Multimodal “synergistic” treatment based on tumour immunological contexture for advanced non-driver non-small cell lung cancer: A myth or reality?. <i>European Journal of Cancer Care</i> , 2020, 29, e13291.	1.5	1
61	In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer. <i>Radiation Oncology</i> , 2020, 15, 252.	2.7	1
62	Combination of pembrolizumab with radiotherapy can change treatment paradigm in metastatic non-driver non-small cell lung cancer: Assembling a path. <i>Clinical Respiratory Journal</i> , 2021, 15, 1139-1144.	1.6	1
63	The impact of residual metabolic primary tumor volume after completion of thoracic irradiation in patients with inoperable stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9049-9049.	1.6	1
64	Why is survival after pembrolizumab affected by previous radiotherapy?. <i>Lancet Oncology</i> , The, 2017, 18, e504.	10.7	1
65	Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve. <i>Cancer</i> , 2022, 128, 2358-2366.	4.1	1
66	123P: Impact of the primary tumor metabolic volume (PT-MV) changes in the course of multimodality treatment on overall survival in patients with locally-advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S109.	1.1	0
67	OC-0144: Maximum response and PCI are important prognostic factors in LD SCLC patients staged with cMRI. <i>Radiotherapy and Oncology</i> , 2016, 119, S65-S66.	0.6	0
68	127P: Maximum treatment response and prophylactic cranial irradiation are important prognostic factors in limited disease small-cell lung cancer patients comprehensively staged with cranial magnetic resonance imaging. <i>Journal of Thoracic Oncology</i> , 2016, 11, S111.	1.1	0
69	Is it time to convert the frequency of radiotherapy in small-cell lung cancer?. <i>Lancet Oncology</i> , The, 2017, 18, e555.	10.7	0
70	114P Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally advanced node-positive non-small cell lung cancer patients with very limited lung function. <i>Journal of Thoracic Oncology</i> , 2018, 13, S63.	1.1	0
71	117P Feasibility of moderate hypofractionated image-guided thoracic irradiation for locally advanced node-positive non-small cell lung cancer patients with very limited lung function. <i>Journal of Thoracic Oncology</i> , 2018, 13, S65.	1.1	0
72	P2.17-18 A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, S859.	1.1	0

#	ARTICLE	IF	CITATIONS
73	P3.01-25 Feasibility of Moderate Hypofractionated Thoracic Irradiation for Non-Small Cell Lung Cancer Patients with Very Limited Lung Function. <i>Journal of Thoracic Oncology</i> , 2018, 13, S876-S877.	1.1	0
74	Chemoradiotherapy of stage III small cell lung cancer: Can we further optimize multimodal treatment of N3 disease based on current evidence?. <i>Clinical Respiratory Journal</i> , 2018, 12, 2534-2535.	1.6	0
75	86P Prophylactic cranial irradiation in SCLC: A survey of German radiation oncology institutions on recommendations for brain imaging. <i>Journal of Thoracic Oncology</i> , 2018, 13, S47.	1.1	0
76	84P Patterns of care for patients with small cell lung cancer: A survey of German radiation oncology institutions on recommendations for prophylactic cranial irradiation. <i>Journal of Thoracic Oncology</i> , 2018, 13, S46.	1.1	0
77	Mediastinal lymph node clearance and anti-PD-1 induction in resected NSCLC. <i>Annals of Oncology</i> , 2018, 29, 1879.	1.2	0
78	PO-0780 Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S403.	0.6	0
79	EP-1268 Primary radiation therapy in stage I/II indolent orbital lymphoma: a single-center analysis. <i>Radiotherapy and Oncology</i> , 2019, 133, S696-S697.	0.6	0
80	EP-1375 Heterogeneity score in inoperable stage III NSCLC patients treated with definitive chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S751.	0.6	0
81	EP-1515 Substantial impact of 68Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S820.	0.6	0
82	External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy. <i>Annals of Oncology</i> , 2019, 30, ii23.	1.2	0
83	The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC. <i>Annals of Oncology</i> , 2019, 30, ii36.	1.2	0
84	Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis. <i>Annals of Oncology</i> , 2019, 30, ii35.	1.2	0
85	Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC. <i>Annals of Oncology</i> , 2019, 30, ii36.	1.2	0
86	Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy. <i>Annals of Oncology</i> , 2019, 30, ii36.	1.2	0
87	Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy. <i>Annals of Oncology</i> , 2019, 30, ii11.	1.2	0
88	A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy. <i>Annals of Oncology</i> , 2019, 30, ii37.	1.2	0
89	Adjuvant radiotherapy additionally to chemotherapy in resected node-positive small cell lung cancer: A role assessment without randomized evidence. <i>Clinical Respiratory Journal</i> , 2020, 14, 498-499.	1.6	0
90	Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18F-FDG-PET/MRI?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 779-786.	1.8	0

#	ARTICLE	IF	CITATIONS
91	Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery. <i>Journal of Thoracic Disease</i> , 2020, 12, 1624-1627.	1.4	0
92	Prognostic impact of inflammatory profiling during and after multimodal treatment for stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20559-e20559.	1.6	0
93	Association of planning target volume with disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20557-e20557.	1.6	0
94	Longitudinal analysis of dynamic changes of T-lymphocytes during multimodal treatment of patients with inoperable stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20503-e20503.	1.6	0
95	Differential role of residual metabolic tumor volume in patients with inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20558-e20558.	1.6	0
96	PD-0810 Salvage Therapies for PSMA PET/CT-positive nodal-only recurrent prostate cancer: Impact on survival, functional outcomes and health-related quality of life. <i>Radiotherapy and Oncology</i> , 2021, 161, S643-S644.	0.6	0
97	Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature. <i>BJR case Reports</i> , 2022, 8, 20200168.	0.2	0
98	Dynamic changes of lymphocyte subsets during multimodal treatment of patients with inoperable stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21011-e21011.	1.6	0
99	Propensity score matching analysis of patients with inoperable stage III NSCLC treated with chemoradio- vs. chemoradioimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21087-e21087.	1.6	0
100	279â€¦Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival. , 2020, , .		0
101	Primary radiation therapy in stage I/II indolent orbital lymphoma â€“ a comprehensive retrospective recurrence and toxicity analysis. <i>European Journal of Haematology</i> , 2022, , .	2.2	0
102	Treatment patterns and prognosis in inoperable stage III NSCLC after concurrent chemoradiotherapy with or without immune checkpoint inhibition: Historical overview.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20578-e20578.	1.6	0
103	Propensity-matched analysis of concurrent/sequential versus sequential immune checkpoint inhibition in inoperable stage III NSCLC patients treated with chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20589-e20589.	1.6	0
104	Absence of CD4⁺ and CD8⁺ T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20590-e20590.	1.6	0
105	Pattern of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy with/without immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20570-e20570.	1.6	0